How This Evidence Evolved
Fat Grafting in Reconstructive Surgery
Coleman structural fat grafting and the oncologic safety debate
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Local events at median 56 months from primary surgery (26 months from lipofilling): lipofilling 8 vs control 19 patients (HR 1.11, 95% CI 0.47-2.64; p=0.792); higher risk in the intraepithelial neoplasia subgroup (37 cases)
Practice recommendations on 5 questions: applications (mainly breast), risks and complications, effect of technique, patient selection, and research advances (recommendation text not in the abstract)
Follow-up studies, subgroup analyses, and real-world validation
Satisfaction through 12 months: patients 50/67, investigators 57/67; blinded MRI breast contour improved in 54/65; no serious injection-procedure-related adverse events, no local recurrences, injection-site cysts in 10 (single arm, no comparator)
Locoregional recurrence at 5 years (Kaplan-Meier): lipofilling 1.6% vs control 4.1%; crude 1.3% (9/719) vs 2.4% (16/670); systemic recurrence 2.4% vs 3.6% (p=0.514)
Current standard of care and ongoing research directions
Landmark Trials in This Story
Locoregional recurrence risk after lipofilling in breast cancer patients.
Local events at median 56 months from primary surgery (26 months from lipofilling): lipofilling 8 vs control 19 patients (HR 1.11, 95% CI 0.47-2.64; p=0.792); higher risk in the intraepithelial neoplasia subgroup (37 cases)
Current applications and safety of autologous fat grafts: a report of the ASPS fat graft task force.
Practice recommendations on 5 questions: applications (mainly breast), risks and complications, effect of technique, patient selection, and research advances (recommendation text not in the abstract)
Prospective trial of adipose-derived regenerative cell (ADRC)-enriched fat grafting for partial mastectomy defects: the RESTORE-2 trial.
Satisfaction through 12 months: patients 50/67, investigators 57/67; blinded MRI breast contour improved in 54/65; no serious injection-procedure-related adverse events, no local recurrences, injection-site cysts in 10 (single arm, no comparator)
Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study.
Locoregional recurrence at 5 years (Kaplan-Meier): lipofilling 1.6% vs control 4.1%; crude 1.3% (9/719) vs 2.4% (16/670); systemic recurrence 2.4% vs 3.6% (p=0.514)
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.